PHARMACOKINETICS OF MITOMYCIN-C IN PELVIC STOPFLOW INFUSION AND HYPOXIC PELVIC PERFUSION WITH AND WITHOUT HEMOFILTRATION - A PILOT-STUDY OFPATIENTS WITH RECURRENT UNRESECTABLE RECTAL-CANCER

This pilot study was conducted to evaluate the advantage in drug deliv ery for regional chemotherapy in patients with unresectable recurrent rectal carcinoma by different methods. For this research, the pharmaco kinetic advantages of mitomycin C delivery by four different methods w ere compared: intraaortic infusion with aortic stopflow; intraaortic i nfusion with inferior vena cava stopflow; intraaortic infusion with ao rtic and inferior caval vein stopflow (hypoxic pelvic perfusion); and hypoxic pelvic perfusion with hemofiltration. The results of this stud y indicate that pelvic stopflow infusion followed by hypoxic pelvic pe rfusion significantly increases mitomycin C concentrations in the bloo d coming from the tumor site. Also, use of hemofiltration reduces mito mycin C levels in peripheral blood after high-dose regional chemothera py. Further investigations involving more patients should be carried o ut in the future to validate these results.